Q3 EPS Forecast for IDEAYA Biosciences Increased by Analyst

Key Points

• Wedbush has increased its Q3 2025 earnings per share forecast for IDEAYA Biosciences from ($0.97) to ($0.94).
• In its latest quarterly report, IDEAYA Biosciences reported a loss of ($0.88) EPS, missing analysts' expectations of ($0.85), but revenue of $6.00 million exceeded the anticipated $3.48 million.
• IDEAYA's stock ratings are largely positive, with a consensus rating of "Moderate Buy" and a price target of approximately $48.09 according to MarketBeat data.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Stock analysts at Wedbush lifted their Q3 2025 earnings per share estimates for shares of IDEAYA Biosciences in a research note issued on Tuesday, August 5th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.94) per share for the quarter, up from their previous estimate of ($0.97). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences' Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.61) EPS, Q1 2026 earnings at ($1.06) EPS, Q2 2026 earnings at ($1.10) EPS, Q3 2026 earnings at ($1.13) EPS, Q4 2026 earnings at ($1.15) EPS, FY2026 earnings at ($4.44) EPS, FY2027 earnings at ($4.05) EPS, FY2028 earnings at ($3.16) EPS and FY2029 earnings at ($0.78) EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. IDEAYA Biosciences's revenue for the quarter was up NaN% compared to the same quarter last year. During the same quarter last year, the company earned ($0.68) earnings per share.

Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group upgraded IDEAYA Biosciences to a "hold" rating and set a $25.00 target price on the stock in a research note on Thursday, July 10th. JPMorgan Chase & Co. increased their target price on IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a research report on Monday, July 28th. Wells Fargo & Company assumed coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price target on the stock. TD Cowen assumed coverage on IDEAYA Biosciences in a research note on Tuesday, July 22nd. They issued a "buy" rating on the stock. Finally, Royal Bank Of Canada raised IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and reduced their target price for the company from $57.00 to $30.00 in a research note on Wednesday, July 9th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, IDEAYA Biosciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.09.

IDEAYA Biosciences Stock Performance

Shares of IDYA opened at $23.63 on Thursday. The stock has a 50 day moving average price of $22.37 and a two-hundred day moving average price of $20.38. The firm has a market capitalization of $2.07 billion, a P/E ratio of -6.23 and a beta of 0.09. IDEAYA Biosciences has a 52 week low of $13.45 and a 52 week high of $40.74.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in IDYA. Raymond James Financial Inc. bought a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at approximately $431,000. JPMorgan Chase & Co. boosted its stake in shares of IDEAYA Biosciences by 244.3% during the 4th quarter. JPMorgan Chase & Co. now owns 274,693 shares of the company's stock worth $7,060,000 after acquiring an additional 194,913 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of IDEAYA Biosciences by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock worth $51,121,000 after acquiring an additional 43,226 shares during the last quarter. FMR LLC lifted its stake in shares of IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock valued at $333,153,000 after buying an additional 327,498 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of IDEAYA Biosciences by 7.9% during the 4th quarter. Legal & General Group Plc now owns 82,442 shares of the company's stock valued at $2,119,000 after buying an additional 6,064 shares in the last quarter. Institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.